Pfizer's new COVID-19 vaccine wins nod in KOR
By Lee, Hye-Kyung | translator Kang, Shin-Kook
24.09.02 05:09:41
°¡³ª´Ù¶ó
0
MFDS has quickly approved the vaccine within 2.5 months of forming a designated review team
KDCA plans to announce a vaccination plan for high-risk patients over 65 years old
¡ãPfizer Korea
The new vaccine, JN.1, developed against emerging COVID-19 subvariant, received approval in South Korea.The Ministry of Food and Drug Safety (MFDS) announced on August 30th that it had completed approval just under two and a half months after application was submitted. A designated review team was formed following the plan announced by the Korea Disease Control and Prevention Agency (KDCA) to initiate COVID-19 vaccination.
The approved vaccine is Pfizer Korea's 'Comirnaty (bretovameran),' containing an mRNA molecule designed to produce a protein from JN.1 subvariant.
Because the SARS-CoV-2 virus mutates over time, vaccines that target subvariants are being developed.
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)